Vaccine development in Staphylococcus aureus

Taking the biofilm phenotype into consideration

Janette M. Harro, Brian Peters, Graeme A. O'May, Nathan Archer, Patrick Kerns, Ranjani Prabhakara, Mark E. Shirtliff

Research output: Contribution to journalShort survey

59 Citations (Scopus)

Abstract

Vaccine development against pathogenic bacteria is an imperative initiative as bacteria are gaining resistance to current antimicrobial therapies and few novel antibiotics are being developed. Candidate antigens for vaccine development can be identified by a multitude of high-throughput technologies that were accelerated by access to complete genomes. While considerable success has been achieved in vaccine development against bacterial pathogens, many species with multiple virulence factors and modes of infection have provided reasonable challenges in identifying protective antigens. In particular, vaccine candidates should be evaluated in the context of the complex disease properties, whether planktonic (e.g. sepsis and pneumonia) and/or biofilm associated (e.g. indwelling medical device infections). Because of the phenotypic differences between these modes of growth, those vaccine candidates chosen only for their efficacy in one disease state may fail against other infections. This review will summarize the history and types of bacterial vaccines and adjuvants as well as present an overview of modern antigen discovery and complications brought about by polymicrobial infections. Finally, we will also use one of the better studied microbial species that uses differential, multifactorial protein profiles to mediate an array of diseases, Staphylococcus aureus, to outline some of the more recently identified problematic issues in vaccine development in this biofilm-forming species.

Original languageEnglish (US)
Pages (from-to)306-323
Number of pages18
JournalFEMS Immunology and Medical Microbiology
Volume59
Issue number3
DOIs
StatePublished - Jan 1 2010

Fingerprint

Biofilms
Staphylococcus aureus
Vaccines
Phenotype
Antigens
Infection
Bacterial Vaccines
Bacteria
Virulence Factors
Coinfection
Sepsis
Pneumonia
History
Genome
Anti-Bacterial Agents
Technology
Equipment and Supplies
Growth
Proteins

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Vaccine development in Staphylococcus aureus : Taking the biofilm phenotype into consideration. / Harro, Janette M.; Peters, Brian; O'May, Graeme A.; Archer, Nathan; Kerns, Patrick; Prabhakara, Ranjani; Shirtliff, Mark E.

In: FEMS Immunology and Medical Microbiology, Vol. 59, No. 3, 01.01.2010, p. 306-323.

Research output: Contribution to journalShort survey

Harro, Janette M. ; Peters, Brian ; O'May, Graeme A. ; Archer, Nathan ; Kerns, Patrick ; Prabhakara, Ranjani ; Shirtliff, Mark E. / Vaccine development in Staphylococcus aureus : Taking the biofilm phenotype into consideration. In: FEMS Immunology and Medical Microbiology. 2010 ; Vol. 59, No. 3. pp. 306-323.
@article{926a06bd90614f54a9290f2d881938c3,
title = "Vaccine development in Staphylococcus aureus: Taking the biofilm phenotype into consideration",
abstract = "Vaccine development against pathogenic bacteria is an imperative initiative as bacteria are gaining resistance to current antimicrobial therapies and few novel antibiotics are being developed. Candidate antigens for vaccine development can be identified by a multitude of high-throughput technologies that were accelerated by access to complete genomes. While considerable success has been achieved in vaccine development against bacterial pathogens, many species with multiple virulence factors and modes of infection have provided reasonable challenges in identifying protective antigens. In particular, vaccine candidates should be evaluated in the context of the complex disease properties, whether planktonic (e.g. sepsis and pneumonia) and/or biofilm associated (e.g. indwelling medical device infections). Because of the phenotypic differences between these modes of growth, those vaccine candidates chosen only for their efficacy in one disease state may fail against other infections. This review will summarize the history and types of bacterial vaccines and adjuvants as well as present an overview of modern antigen discovery and complications brought about by polymicrobial infections. Finally, we will also use one of the better studied microbial species that uses differential, multifactorial protein profiles to mediate an array of diseases, Staphylococcus aureus, to outline some of the more recently identified problematic issues in vaccine development in this biofilm-forming species.",
author = "Harro, {Janette M.} and Brian Peters and O'May, {Graeme A.} and Nathan Archer and Patrick Kerns and Ranjani Prabhakara and Shirtliff, {Mark E.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1574-695X.2010.00708.x",
language = "English (US)",
volume = "59",
pages = "306--323",
journal = "Pathogens and Disease",
issn = "2049-632X",
publisher = "John Wiley & Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Vaccine development in Staphylococcus aureus

T2 - Taking the biofilm phenotype into consideration

AU - Harro, Janette M.

AU - Peters, Brian

AU - O'May, Graeme A.

AU - Archer, Nathan

AU - Kerns, Patrick

AU - Prabhakara, Ranjani

AU - Shirtliff, Mark E.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Vaccine development against pathogenic bacteria is an imperative initiative as bacteria are gaining resistance to current antimicrobial therapies and few novel antibiotics are being developed. Candidate antigens for vaccine development can be identified by a multitude of high-throughput technologies that were accelerated by access to complete genomes. While considerable success has been achieved in vaccine development against bacterial pathogens, many species with multiple virulence factors and modes of infection have provided reasonable challenges in identifying protective antigens. In particular, vaccine candidates should be evaluated in the context of the complex disease properties, whether planktonic (e.g. sepsis and pneumonia) and/or biofilm associated (e.g. indwelling medical device infections). Because of the phenotypic differences between these modes of growth, those vaccine candidates chosen only for their efficacy in one disease state may fail against other infections. This review will summarize the history and types of bacterial vaccines and adjuvants as well as present an overview of modern antigen discovery and complications brought about by polymicrobial infections. Finally, we will also use one of the better studied microbial species that uses differential, multifactorial protein profiles to mediate an array of diseases, Staphylococcus aureus, to outline some of the more recently identified problematic issues in vaccine development in this biofilm-forming species.

AB - Vaccine development against pathogenic bacteria is an imperative initiative as bacteria are gaining resistance to current antimicrobial therapies and few novel antibiotics are being developed. Candidate antigens for vaccine development can be identified by a multitude of high-throughput technologies that were accelerated by access to complete genomes. While considerable success has been achieved in vaccine development against bacterial pathogens, many species with multiple virulence factors and modes of infection have provided reasonable challenges in identifying protective antigens. In particular, vaccine candidates should be evaluated in the context of the complex disease properties, whether planktonic (e.g. sepsis and pneumonia) and/or biofilm associated (e.g. indwelling medical device infections). Because of the phenotypic differences between these modes of growth, those vaccine candidates chosen only for their efficacy in one disease state may fail against other infections. This review will summarize the history and types of bacterial vaccines and adjuvants as well as present an overview of modern antigen discovery and complications brought about by polymicrobial infections. Finally, we will also use one of the better studied microbial species that uses differential, multifactorial protein profiles to mediate an array of diseases, Staphylococcus aureus, to outline some of the more recently identified problematic issues in vaccine development in this biofilm-forming species.

UR - http://www.scopus.com/inward/record.url?scp=77954637231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954637231&partnerID=8YFLogxK

U2 - 10.1111/j.1574-695X.2010.00708.x

DO - 10.1111/j.1574-695X.2010.00708.x

M3 - Short survey

VL - 59

SP - 306

EP - 323

JO - Pathogens and Disease

JF - Pathogens and Disease

SN - 2049-632X

IS - 3

ER -